RGC - Regencell Corp Forward Price-to-Revenue Multiple
Stringent certification requirements for Chinese medicine drugs create significant barriers to entry for Regencell Bioscience (RGC). The forward P/S trend illustrates the current valuation, where the parameter mark equals . However, a lack of alliances with Big Pharma limits growth, while the clinical trial stage coupled with zero sales leads to persistent losses and a reliance on external financing.
RGC (Regencell Corp): analytical breakdowns and indicator data
- market price and analyst price targets:
- market capitalization statistics:
- business book valuation details:
- debt and solvency information:
Debt to Equity Regencell Bioscience|RGC - Long-Term Liabilities to Capital|Short-Term Debt to Equity Regencell Bioscience|RGC - Company Total Debt Obligations|Debts to Book Capitalization Regencell Corp|RGC - Company Long-Term Liabilities|Company Short-Term Debts Regencell Bioscience|Quick Ratio regencellbioscience.com
- financial results and valuation multiples details:
RGC - Company Net Income|Expected Profit Regencell Bioscience|RGC - Price to Earnings Multiple|Forward P/E Multiple Regencell|RGC - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Regencell Corp|RGC - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Regencell Bioscience|RGC - Earnings per share for the trailing year|Quarterly EPS earnings growth regencellbioscience.com|RGC - Net earnings per share change in current year|Earnings growth forecast for next year Regencell Bioscience
- sales revenue and business income indicators:
Comprehensive company analysis:Regencell Bioscience Holdings Limited RGC
For Regencell Bioscience (RGC), whose developments are in early stages without market pricing power, the forward P/S serves as a gauge of speculative expectations regarding future sales. By analyzing changes in the forward P/S, an investor can observe the ratio of current market capitalization to projected revenue, stripped of volatility, which is critical for assessing the company's valuation prior to the commercial launch of its drugs.
Competitors of Regencell Bioscience (RGC)
Price-to-Projected Revenue Ratio Biogen BIIB|Neurocrine - Price-to-Projected Revenue Ratio|AXSM: Forward Price-to-Revenue Multiple|Forward Price to Sales ACAD (ACADIA Corp)|XENE: Forward P/S Multiple|VKTX (vikingtherapeutics.com) - Price-to-Projected Revenue Ratio|SUPN (Supernus) - Forward P/S Multiple|Catalyst Pharma (CPRX) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Denali Therapeutics Inc (DNLI)|HRMY - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Biohaven Ltd. BHVN|Market Cap to Expected Sales Ratio amylyx.com (AMLX)|Trevi Therapeutics, Inc. - Forward P/S Multiple|Praxis Precision Medicines Inc (PRAX) - Forward Price-to-Revenue Multiple|AVXL: Forward P/S Multiple|CBLL - Market Cap to Expected Sales Ratio|PRTA (Prothena Biosciences) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Alector Therapeutics ALEC|Price-to-Projected Revenue Ratio Annexon (ANNX)|omeros.com - Market Cap to Projected Revenue|Forward P/S Multiple NGNE (Neurogene Corp)|ACIU - Forward Price-to-Revenue Multiple|Voyager Therapeutics - Forward P/S Multiple|Market Cap to Future Revenue Ratio neumoratx.com|Scilex (SCLX) - Price-to-Projected Revenue Ratio|Tevogen Bio Holdings Inc. - Forward Price to Sales|ACOG (Alpha Cognition Inc) - Forward P/S Multiple|CGTX - Projected Price to Revenue|Forward P/S Multiple IKT|Forward Price-to-Revenue Multiple cassavasciences.com SAVA|Price-to-Projected Revenue Ratio Assertio ASRT|COYA: Market Cap to Projected Revenue|VistaGen Therapeutics Inc - Forward P/S Multiple|Market Cap to Future Revenue Ratio Ovid Therapeutics Inc.|ABOS (Acumen Pharmaceuticals) - Forward Price-to-Revenue Multiple|cervomed.com (CRVO) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Alterity Therapeutics Ltd.|CLNN: Forward Price to Sales|Price-to-Projected Revenue Ratio PepGen Inc. (PEPG)|JUNS - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Relmada Therapeutics RLMD|Forward Price to Sales ANVS|Grace Tx - Forward P/S Multiple|Market Cap to Future Revenue Ratio Firefly Neuroscience, Inc.|KLTO: Forward P/S Multiple|Projected Price to Revenue NeuroSense Therapeutics Ltd. NRSN|RVPH (Reviva Pharmaceuticals) - Forward P/S Multiple|Market Cap to Future Revenue Ratio MetaVia, Inc. MTVA|Price-to-Projected Revenue Ratio NeurAxis (NRXS)|heliusmedical.com - Market Cap to Projected Revenue|Forward P/S Multiple PASG (Passage Bio)|NEUP - Forward Price-to-Revenue Multiple|Minerva Neurosciences - Forward P/S Multiple|Market Cap to Future Revenue Ratio athira.com|Addex Therapeutics Ltd (ADXN) - Price-to-Projected Revenue Ratio|ALZN (Alzamend Neuro) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio Cyclerion Therapeutics Inc.|Price-to-Projected Revenue Ratio PTIX|Forward Price-to-Revenue Multiple KTTA (Pasithea Therapeutics)|CRGT (cortigent.com) - Forward Price to Sales|Forward P/S Multiple ATXI (Avenue Therapeutics, Inc.)|Brainstorm Cell Therapeutics Inc. - Price-to-Projected Revenue Ratio|Cara Therapeutics, Inc - Forward P/S Multiple|Market Cap to Expected Sales Ratio Chromocell CHRO|eliemtx.com (ELYM) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Intra-Cellular Therapies, Inc. (ITCI)|Price-to-Projected Revenue Ratio Longboard Pharmaceuticals, Inc.|Marinus Pharmaceuticals Inc (MRNS) - Market Cap to Expected Sales Ratio|Forward P/S Multiple NKGN|Forward Price-to-Revenue Multiple NeuroBo Pharma NRBO|Forward P/S Multiple SAGE (Sage Therapeutics, Inc.)|Market Cap to Expected Sales Ratio synaptogen.com (SNPX)|Trevena - Forward P/S Multiple|Market Cap to Future Revenue Ratio Vigil Neuroscience|Anew Medical (WENA) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue CERE
